Dolutegravir Sodium molecular structure

Dolutegravir Sodium

Also known as: Tivicay, Dolutec, Dovato and Triumeq components, TLD fixed-dose combinations

CAS Number: 1051375-19-9

HIV-1 Integrase Strand Transfer Inhibitor (INSTI)

Pharmacopeia Standards

USPIP

Mechanism of Action

Dolutegravir binds the active site of HIV-1 integrase and chelates the two magnesium ions held by the catalytic DDE triad within the intasome. This blocks the strand transfer step in which viral DNA ends are joined to host chromosomal DNA, halting integration and productive infection. Its slow dissociation from the intasome underpins a high barrier to resistance relative to earlier integrase inhibitors.

Technical Specifications

Generic / INN NameDolutegravir Sodium
CAS Registry Number1051375-19-9
Molecular FormulaC20H18F2N3NaO5
Molecular Weight441.36 g/mol g/mol
Typical PurityNot less than 98.5% on anhydrous basis; any unspecified impurity NMT 0.10%
Storage ConditionsStore below 25 degrees C in tightly closed, light-resistant containers with desiccant; protect from moisture.
Shelf Life36 months from date of manufacture in original sealed packing
CategoryAntiretrovirals (HIV)

Specifications are indicative and intended for sourcing reference only. Always confirm against the supplier's Certificate of Analysis and the applicable pharmacopeial monograph before issuing a purchase specification.

Typical Applications

Bulk API for 50 mg adult tablets, 10 mg paediatric dispersible tablets, and the WHO-preferred tenofovir-lamivudine-dolutegravir fixed-dose combination supplied into global HIV programmes.

Manufacturers (0+)

View all →
No manufacturers listed yet. Register your company to appear here.